Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cAd3-EBO
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
cAd3-EBO (VRC-EBOADC069-00-VP) is a bivalent viral vector vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with GlaxoSmithKline (GSK). The vaccine utilizes a replication-deficient chimpanzee adenovirus type 3 (cAd3) vector to deliver genetic material encoding the glycoproteins of both the Zaire and Sudan strains of the Ebola virus. By expressing these antigens, the vaccine is designed to stimulate both humoral (antibody) and cellular (T-cell) immune responses to prevent Ebola Virus Disease (EVD). It was evaluated in Phase 1 and Phase 1b clinical trials (such as VRC 207) to assess safety and immunogenicity, particularly during the 2014 West Africa Ebola outbreak response.
- Other names
- cAd3-EBOVcAd-3-EBOVcAd 3-EBOVbivalent cAd3-Ebola vaccineChimpanzee Adenovirus Type 3 Ebola Vaccine
02
Targets
Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on cAd3-EBO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cAd3-EBO.